radiomics.bio Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
31
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$6.93M
- Investors
-
5
radiomics.bio General Information
Description
Developer of an artificial intelligence-powered medical imaging and advanced statistics platform designed to optimise the development of oncology treatments. The company provides treatment response quantification, exploration and validation of drug mechanisms of action, predictive tools, and an integrated image management system, enabling the healthcare industry to streamline image collection, centralise quality assessment, and make insight-based decisions in clinical development.
Contact Information
Website
www.radiomics.bioCorporate Office
- Boulevard Patience et Beaujonc 3
- LégiaPark
- 4000 Liege
- Belgium
Corporate Office
- Boulevard Patience et Beaujonc 3
- LégiaPark
- 4000 Liege
- Belgium
radiomics.bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series B) | 17-Nov-2021 | $6.93M | Completed | Generating Revenue | ||
| 5. Early Stage VC | 01-Feb-2018 | Completed | Generating Revenue | |||
| 4. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 3. Accelerator/Incubator | 01-Jan-2018 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 01-Jan-2017 | Completed | Startup | |||
| 1. Accelerator/Incubator | Completed | Startup |
radiomics.bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Class C | ||||||||
| Class B | ||||||||
| Class B | 80 | $17.33 | $17.33 | 1x | $17.33 | 0.64% | ||
| Preference | 1,830 | $17.33 | $17.33 | 1x | $17.33 | 14.56% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
radiomics.bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
radiomics.bio Patents
radiomics.bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023016844-A1 | Methods, systems, storage media and apparatus for increased classification, prediction or segmentation accuracy of medical conditions in biomedical images through attention maps | Inactive | 12-Aug-2021 | ||
| EP-4381425-A1 | Methods, systems, storage media and apparatus for training a biomedical image analysis model to increase prediction accuracy of a medical or cosmetic condition | Inactive | 04-Aug-2021 | ||
| US-20240164736-A1 | Methods, systems, storage media and apparatus for training a biomedical image analysis model to increase prediction accuracy of a medical or cosmetic condition | Inactive | 04-Aug-2021 | ||
| WO-2023012079-A1 | Methods, systems, storage media and apparatus for training a biomedical image analysis model to increase prediction accuracy of a medical or cosmetic condition | Inactive | 04-Aug-2021 | ||
| EP-4315238-A1 | Methods and systems for biomedical image segmentation based on a combination of arterial and portal image information | Inactive | 02-Apr-2021 | G06T7/0012 |
radiomics.bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
radiomics.bio Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Epimède | Venture Capital | Minority | ||
| LeanSquare | Venture Capital | Minority | ||
| Noshaq | Venture Capital | Minority | ||
| QB3 | Accelerator/Incubator | |||
| Matwin | Accelerator/Incubator |
radiomics.bio Investments (1)
radiomics.bio’s most recent deal was a Grant with DeuterOncology for . The deal was made on 07-Apr-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| DeuterOncology | 07-Apr-2023 | Grant | Drug Discovery |
radiomics.bio FAQs
-
When was radiomics.bio founded?
radiomics.bio was founded in 2016.
-
Where is radiomics.bio headquartered?
radiomics.bio is headquartered in Liege, Belgium.
-
What is the size of radiomics.bio?
radiomics.bio has 31 total employees.
-
What industry is radiomics.bio in?
radiomics.bio’s primary industry is Decision/Risk Analysis.
-
Is radiomics.bio a private or public company?
radiomics.bio is a Private company.
-
What is the current valuation of radiomics.bio?
The current valuation of radiomics.bio is .
-
What is radiomics.bio’s current revenue?
The current revenue for radiomics.bio is .
-
How much funding has radiomics.bio raised over time?
radiomics.bio has raised $11.8M.
-
Who are radiomics.bio’s investors?
Epimède, LeanSquare, Noshaq, QB3, and Matwin have invested in radiomics.bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
